EphA2 Up-regulation induced by deoxycholic acid in human colon carcinoma cells, an involvement of extracellular signal-regulated kinase and p53-independence

• Published in: Journal of cancer research and clinical oncology 2003-12, Vol.129 (12), p.703-708
• Main Authors: LI, Zhongyou, TANAKA, Masamitsu, KATAOKA, Hideki, NAKAMURA, Ritsuko, SANJAR, Ravshanov, SHINMURA, Kazuya, SUGIMURA, Haruhiko
• Format: Article
• Language: English
• Subjects: Acids; Biological and medical sciences; Blotting, Western; Carcinoma - metabolism; Cell Line, Tumor; Cell physiology; Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes; Cells; Colonic Neoplasms - metabolism; Colorectal cancer; Deoxycholic Acid - pharmacology; Dose-Response Relationship, Drug; Fundamental and applied biological sciences. Psychology; Gene Expression Regulation, Neoplastic - drug effects; Humans; Mitogen-Activated Protein Kinases - drug effects; Mitogen-Activated Protein Kinases - metabolism; Molecular and cellular biology; Receptor, EphA2 - drug effects; Receptor, EphA2 - metabolism; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction - drug effects; Time Factors; Tumor Suppressor Protein p53 - metabolism; Up-Regulation - drug effects
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-003-0493-z

The EphA2 receptor protein tyrosine kinase gene has been shown to be over-expressed or functionally altered in a number of human tumors, including colon cancer, but little is known about the regulation of this new oncoprotein. In order to explore the mechanism of EphA2 up-regulation in cancer cells, we examined the change of expression of EphA2 gene induced by deoxycholic acid (DCA) and elucidated its possible pathways in human colon cancer cells. Western blot and RT-PCR were used to assess the protein expression and messenger RNA in several colon cancer cell lines, which harbor various p53 status. The inhibition study to interfere the MAPK pathway was performed by using various chemicals and by transfecting dominant negative mutant plasmids. Up-regulation of EphA2 induced by DCA was observed in a dose- and time-dependent fashion both in mRNA and protein levels. This regulation is constant regardless of p53 status including wild, mutant or knocked out in the colon cell lines used. This induction was in part blocked by either erk1/2 inhibitors or dominant negative mutants erk1/2 plasmids. These results suggest that DCA induced up-regulation of EphA2 in colon cancer cells is due to activation of erk1/2 cascade, and is p53-independent. Taken together with the roles of EphA2 and DCA in tumorigenesis, which have been independently reported, our observation will provide a new mechanistic basis of DCA commitment in carcinogenesis.